A study of the reliability, validity and responsiveness of the HIV overview of problems evaluation system (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection.
The objective of this study was to evaluate the feasibility, reliability, validity and responsiveness of the HIV Overview of Problems Evaluation System (HOPES) in a Dutch sample. The HOPES was administered three times in a one-year period to a sample of 106 outpatients with a symptomatic HIV-infection (n = 23) or AIDS (n = 83). The HOPES is a self-report HIV-specific quality of life (QOL) questionnaire including five scales: physical, psycho-social and sexual functioning, medical interaction and partner relationship. QOL was also assessed with the EORTC Quality of Life Questionnaire (EORTC QLQ-C30), a 30-item self-report instrument. Clinical data included Centers for Disease Control and Prevention (CDC) stage, date of diagnosis and CD4 cell count. Patients needed approximately 20-30 minutes to complete the questionnaire. The five scales had good internal consistency reliability. Multitrait scaling analysis provided moderate support for item discriminant and convergent validity. The HOPES exhibited adequate levels of construct validity: (1) the inter-scale correlations and correlations with the EORTC QLQ-C30 were in the predicted direction; (2) it discriminated clearly between patients with AIDS and ARC and (3) it was able to document changes in QOL over time. Moreover, the HOPES was responsive to changes in clinical status over time as indicated by CD4 counts. This study provides further evidence of the reliability and validity of the HOPES and shows that this instrument is responsive to changes in CD4 cell counts.
De Boer
J B
JB
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sprangers
M A
MA
Aaronson
N K
NK
Lange
J M
JM
van Dam
F S
FS
D000386:AIDS-Related Complex / Q000523:psychology / Q000628:therapy; D000163:Acquired Immunodeficiency Syndrome / Q000523:psychology* / Q000628:therapy; D000203:Activities of Daily Living / Q000145:classification / Q000523:psychology*; D000223:Adaptation, Psychological; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D015658:HIV Infections / Q000523:psychology* / Q000628:therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D009426:Netherlands; D011581:Psychological Tests / Q000706:statistics & numerical data*; D011594:Psychometrics; D011788:Quality of Life; D015203:Reproducibility of Results; D012803:Sick Role; D016896:Treatment Outcome; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects
D016898:Interferon-alpha; D015215:Zidovudine